Safety
death, hypercholesterolemia, anemia
HYPERCHOLESTEROLEMIA, ANEMIA
All 70 subjects were included in the safety assessment. Of these, 55 (78.6%) subjects experienced at least one AE, including 43 (76.8%) of the 56 subjects in the SHR7280 group and 12 (85.7%) of the 14 subjects in the placebo group (Table Safety resultsData are The majority of AEs were mild in severity, and none were reported as severe. Only two moderate AEs were reported, which were both judged as treatment-related. One moderate AE was anemia from the 350 mg BID group of SHR7280, and the other was hypercholesterolemia from the placebo group, both of which resolved with appropriate intervention. No serious AEs occurred, and no AEs resulted in treatment discontinuation or death. The incidence and severity of AEs were not dose-dependent.Forty-two (75.0%) subjects in the SHR7280 group and 12 (85.7%) subjects in the placebo group experienced treatment-related AEs, with increased blood bilirubin (30.4%) and increased alanine aminotransferase (16.1%) being the most common ones in the SHR7280 group.